Improved post-prandial ghrelin response by nateglinide or acarbose therapy contributes to glucose stability in Type 2 diabetic patients

Journal of Endocrinological Investigation

Volumn 36, Issue 7, 2013, Pages 489-496

  Zheng, F ^a   Yin, X ^a   Lu, W ^a   Zhou, J ^a   Yuan, H ^a   Li, H ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Acarbose; Ghrelin response; Glucose stability; Nateglinide; Type 2 diabetes

Indexed keywords

ACARBOSE; GHRELIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; NATEGLINIDE;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC PATIENT; DYSGLYCEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESPONSE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT RESPONSE;

ACARBOSE; ADULT; BLOOD GLUCOSE; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; FEMALE; GHRELIN; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PHENYLALANINE; POSTPRANDIAL PERIOD;

EID: 84881407218     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8811     Document Type: Article

References (26)

1. Marcovecchio ML, Lucantoni M, Chiarelli F. Role of chronic and acute hyperglycemia in the development of diabetes complications. Diabetes Technol Ther 2011, 13: 389-94.
2. Colette C, Monnier L. Acute glucose fluctuations and chronic sustained hyperglycemia as risk factors for cardiovascular diseases in patients with type 2 diabetes. Horm Metab Res 2007, 39: 683-6.
3. Zhou J, Li H, Ran X, et al. Establishment of normal reference ranges for glycemic variability in Chinese subjects using continuous glucose monitoring. Med Sci Monit 2011, 17: CR9-13.
4. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006, 295: 1681-7.
5. Kohnert KD, Augstein P, Zander E, et al. Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care 2009, 32: 1058-62.
6. Tong J, Prigeon RL, Davis HW, et al. Ghrelin suppresses glucosestimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes 2010, 59: 2145-51.
7. Dezaki K, Kakei M, Yada T. Ghrelin uses Galphai2 and activates voltage-dependent K+ channels to attenuate glucose-induced Ca2+ signaling and insulin release in islet beta-cells: novel signal transduction of ghrelin. Diabetes 2007, 56: 2319-27.
8. Tschöp M, Wawarta R, Riepl RL, et al. Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest 2001, 24: RC19-21.
9. Rudovich N, Möhlig M, Otto B, et al. Effect of meglitinides on postprandial ghrelin secretion pattern in type 2 diabetes mellitus. Diabetes Technol Ther 2010, 12: 57-64.
10. Erdmann J, Lippl F, Wagenpfeil S, Schusdziarra V. Differential association of basal and postprandial plasma ghrelin with leptin, insulin, and type 2 diabetes. Diabetes 2005, 54: 1371-8.
11. English PJ, Ashcroft A, Patterson M, et al. Metformin prolongs the postprandial fall in plasma ghrelin concentrations in type 2 diabetes. Diabetes Metab Res Rev 2007, 23: 299-303.
12. Martin CK, Gupta AK, Smith SR, Greenway FL, Han H, Bray GA. Effect of pioglitazone on energy intake and ghrelin in diabetic patients. Diabetes Care 2010, 33: 742-4.
13. Hanefeld M, Bouter KP, Dickinson S, Guitard C. Rapid and shortacting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 2000, 23: 202-7.
14. Hanefeld M, Fischer S, Schulze J, et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991, 14: 732-7.
15. Kim MK, Suk JH, Kwon MJ, et al. Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes. Diabetes Res Clin Pract 2011, 92: 322-8.
16. Marbury T, Huang WC, Strange P, Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 1999, 43: 155-66.
17. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Diabetes Care 1994, 17: 561-6.
18. Schöfl C, Horn R, Schill T, Schlösser HW, Müller MJ, Brabant G. Circulating ghrelin levels in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87: 4607-10.
19. Flanagan DE, Evans ML, Monsod TP, et al. The influence of insulin on circulating ghrelin. Am J Physiol Endocrinol Metab 2003, 284: E313-6.
20. Broglio F, Arvat E, Benso A, Gottero C, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 2001, 86: 5083-6.
21. Cederberg H, Rajala U, Koivisto VM, Jokelainen J, et al. Unacylated ghrelin is associated with changes in body composition and body fat distribution during long-term exercise intervention. Eur J Endocrinol 2011, 165: 243-8.
22. Murdolo G, Lucidi P, Di Loreto C, et al. Insulin is required for prandial ghrelin suppression in humans. Diabetes 2003, 52: 2923-7.
23. Esler WP, Rudolph J, Claus TH, et al. Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology 2007, 148: 5175-85.
24. Murata M, Okimura Y, Iida K, et al. Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. J Biol Chem 2002, 277: 5667-74.
25. Briatore L, Andraghetti G, Cordera R. Acute plasma glucose increase, but not early insulin response, regulates plasma ghrelin. Eur J Endocrinol 2003, 149: 403-6.
26. Sakata I, Park WM, Walker AK, et al. Glucose-mediated control of ghrelin release from primary cultures of gastric mucosal cells. Am J Physiol Endocrinol Metab 2012, 302: E1300-10.